Want to see AU:IMC full AI Analyst Report?
Immuron Limited (IMC) AI Stock Analysis
Immuron Limited
(ASX:IMC)
The score is primarily held down by weak financial sustainability—ongoing losses and persistent negative free cash flow—despite improving revenue and strong gross margins. Technicals also remain weak with price below key moving averages and negative/soft momentum indicators. Valuation provides limited support due to negative earnings (negative P/E) and no dividend yield data.
Immuron Limited (IMC) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 12.91M
- Dividend Yield
- ―
- Average Volume (3M)
- 537.76K
- Price to Earnings (P/E)
- -3.1
- Beta (1Y)
- 0.01
- Revenue Growth
- 5.85%
- EPS Growth
- 45.13%
- Country
- Australia
- Employees
- 8
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Immuron Limited Business Overview & Revenue Model
Company Description
Immuron Limited, an Australian biopharmaceutical firm founded in 1994 and headquartered in Carlton, is dedicated to the exploration, advancement, and worldwide commercialization of polyclonal antibodies. Operating across two divisions—Research and De...
How the Company Makes Money
Immuron makes money primarily through the sale of its commercial products and, to the extent applicable, through collaborative/partnering arrangements tied to development and commercialization of its candidates. Key revenue streams include: 1) Produc...
Immuron Limited Financial Statement Overview
Summary
Revenue has scaled to ~7.7m (2026) with consistently strong gross margins (~65–73%), but the company remains loss-making with deeply negative net margin (~-50%). Cash flow is the main weakness with persistent negative operating and free cash flow despite some improvement in 2026, implying continued reliance on external funding. The balance sheet is a relative strength with minimal leverage and positive equity, but ongoing losses continue to erode value.
Income Statement
36NegativeBalance Sheet
58NeutralCash Flow
32Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.71M | 7.71M | 7.29M | 4.90M | 1.80M | 765.19K |
| Gross Profit | 4.98M | 4.98M | 4.77M | 3.34M | 1.31M | 523.50K |
| EBITDA | -4.74M | -4.74M | -5.31M | -6.19M | -3.80M | -3.08M |
| Net Income | -3.84M | -3.84M | -5.22M | -6.94M | -3.79M | -2.85M |
Balance Sheet | ||||||
| Total Assets | 12.99M | 12.99M | 10.13M | 15.55M | 21.99M | 24.86M |
| Cash, Cash Equivalents and Short-Term Investments | 9.02M | 9.02M | 5.87M | 11.66M | 18.99M | 22.11M |
| Total Debt | 0 | 0 | 117.13K | 173.50K | 189.09K | 209.79K |
| Total Liabilities | 1.99M | 1.99M | 2.06M | 2.84M | 2.37M | 1.68M |
| Stockholders Equity | 11.01M | 11.01M | 8.07M | 12.71M | 19.62M | 23.18M |
Cash Flow | ||||||
| Free Cash Flow | -3.07M | -3.07M | -6.14M | -5.56M | -2.50M | -3.14M |
| Operating Cash Flow | -3.07M | -3.07M | -6.14M | -5.56M | -2.49M | -3.13M |
| Investing Cash Flow | 3.03M | 3.03M | -2.90M | 327.56K | -2.74M | 11.74K |
| Financing Cash Flow | 6.49M | 6.49M | 199.75K | 829 | -35.02K | -36.26K |
Immuron Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IMC, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 50.05 is Neutral, neither overbought nor oversold. The STOCH value of 59.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IMC.
Immuron Limited Risk Analysis
Immuron Limited disclosed 62 risk factors in its most recent earnings report. Immuron Limited reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
2 New RisksImmuron Limited Peers Comparison
Overall Rating
AU:BIO71Outperform
AU:AVE50Neutral
AU:ANR44Neutral- AU:IMC42Neutral
AU:EZZ42Neutral
AU:AGN38.55Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:BIO | 71Outperform | AUD 83.31M | 22.36 | 46.74% | ― | 29.68% | 1520.00% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:AVE | 50Neutral | AUD 54.09M | -9.33 | -211.39% | ― | -46.59% | 9.09% |
| AU:ANR | 44Neutral | AUD 2.53M | -2.35 | -101.34% | ― | ― | 64.58% |
| AU:IMC | 42Neutral | AUD 12.91M | -3.10 | -31.88% | ― | 5.85% | 45.13% |
| AU:EZZ | 42Neutral | AUD 14.35M | -2.70 | -20.36% | 13.17% | -30.79% | -177.68% |
| AU:AGN | 39Underperform | AUD 14.77M | -10.85 | -29.22% | ― | ― | 81.00% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:IMC | Immuron Limited | 0.04 | -0.04 | -49.37% | |
| AU:AVE | Avecho Biotechnology Limited | 0.01 | 0.00 | 40.00% | |
| AU:ANR | Anatara Lifesciences Ltd | 0.01 | 0.00 | 0.00% | |
| AU:AGN | Argenica Therapeutics Ltd | 0.12 | -0.17 | -59.65% | |
| AU:EZZ | EZZ Life Science Holdings Ltd. | 0.30 | -1.91 | -86.21% | |
| AU:BIO | Biome Australia Ltd | 0.36 | -0.09 | -20.00% |
Immuron Limited Corporate Events
Immuron CEO to showcase infectious-disease portfolio at Emerging Growth Conference
Immuron Limited, an Australian biopharmaceutical company specializing in orally delivered targeted polyclonal antibodies for infectious diseases, is best known for its anti–travelers’ diarrhea product Travelan, which is approved or regist...
Immuron trims ATM facility to US$2 million while preserving funding flexibility
Immuron Limited has updated its existing at-the-market equity offering facility with H.C. Wainwright & Co., reducing the maximum aggregate capacity to about US$2.0 million while keeping the structure in place. The company retains full discretion...
Immuron lifts Q1 sales on Travelan surge despite U.S. softness
Immuron reported unaudited global Q1 sales of AUD$2.2 million for the quarter ended September 30, 2026, a 9% rise year-on-year and 5% sequential growth, driven primarily by strong performance in Australia and Canada. Australian sales rose 14% on the...
Immuron CEO to Spotlight Oral Antibody Platform at Emerging Growth Conference
Immuron has announced that Chief Executive Officer Steven Lydeamore will deliver a virtual presentation at the Emerging Growth Conference on October 28, 2026, targeting U.S. investors during the afternoon Eastern Time session. The event offers curren...
Immuron advances Travelan after Phase 2 data published in Nature journal
Immuron has reported that data from its Phase 2 randomized, placebo-controlled trial of a once-daily oral formulation of Travelan for prevention of travelers’ diarrhea has been published in Nature’s Scientific Reports. The study, partly f...
Immuron Files 2026 Corporate Governance Statement with ASX
Immuron Limited has lodged its Appendix 4G and confirmed that its corporate governance statement for the year ended 30 June 2026 is available on its website in accordance with ASX Listing Rule requirements. The statement, approved by the board as at...
Immuron Releases Comprehensive 2026 Annual Report
Immuron Limited has released its 2026 Annual Report, outlining a comprehensive review of operations and activities alongside its Form 20-F filing and consolidated financial statements. The report also includes an auditor’s independence declarat...
Immuron Showcases Oral Antibody Platform at Coffee Microcaps Conference
Immuron’s chief executive officer, Steven Lydeamore, is presenting the company’s story and product portfolio to investors at the Coffee Microcaps Conference in Sydney, underscoring its positioning as a niche infectious disease and gastroi...
Immuron to Launch Calmino’s Digestive Health Device PROIBS in U.S. Market
Immuron Limited has signed an exclusive U.S. distribution agreement with Sweden’s Calmino group AB to launch PROIBS®, a European-certified medical device for abdominal pain, bloating and irregular bowel movements, following its introductio...
Immuron Issues FY26 Preliminary Results With Safe Harbor Caution
Immuron Limited has released preliminary financial results for fiscal year 2026 for its listings on Nasdaq and the ASX, noting that these figures remain subject to audit review. The company also cautions that statements in the presentation are forwar...
Immuron Narrows Loss as Travelan Sales Lift Revenue and Cash Reserves
Immuron Limited reported a 5.9% rise in revenue to $7.7 million for the year ended 30 June 2026, driven mainly by higher Travelan sales in Australia and North America, while its net loss narrowed 26.4% to $3.8 million as research and development spen...
Immuron CEO to Spotlight Oral Immunotherapy Portfolio at Emerging Growth Conference
Immuron’s chief executive officer, Steven Lydeamore, is scheduled to present at the Emerging Growth Conference on August 19, 2026, highlighting the company’s strategy and its suite of oral immunotherapy products. The appearance underscore...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 16, 2026